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A B S T R A C T
Reduced left ventricular ejection fraction (≤40%) and/or signs of clinical heart failure 
after acute myocardial infarction (AMI) are associated with a relatively high inci-
dence of mortality and hospitalization for heart failure. The potential of eplerenone 
to impact on mortality and morbidity of post-infarction heart failure patients was the 
subject of the EPHESUS trial (Eplerenone Post-Acute Myocardial Infarction Heart 
Failure Efficacy and Survival Study). That trial concluded that eplerenone reduced 
total mortality by 31%, cardiovascular mortality by 32% and sudden cardiac death 
by 37% within 30 days of randomization after AMI. Risk reduction in mortality with 
eplerenone seemed to occur as early as 10 days after randomization and continued 
through the end of the study. In conclusion, eplerenone improves survival in heart 
failure patients post-AMI.
Reduced left ventricular ejection fraction (LVEF) (≤40%) and/or signs of clinical 
heart failure after acute myocardial infarction (AMI) are associated with a relatively 
high incidence of mortality and hospitalization for heart failure.1 Of importance, pa-
tients with signs of heart failure post-infarction have a three- to four-fold increased 
risk of in-hospital death and a 55% increased risk of dying within 30 days after AMI 
in comparison with patients with an acute infarction but no signs of heart failure.1,2 
This early increase in risk in patients with a reduced LVEF and clinical signs of heart 
failure argues for therapeutic interventions as early as possible after AMI.
It is already well established that aldosterone blockade reduces the rate of death 
due to progressive heart failure and the rate of sudden death from cardiac causes, 
among patients with severe heart failure due to left ventricular systolic dysfunction.3 
Aldosterone blockade also prevents ventricular remodeling and collagen formation 
in patients with left ventricular systolic dysfunction after AMI.
Eplerenone is an aldosterone blocker that selectively blocks the mineralocorticoid 
receptor and not the glycocorticoid, progesterone or androgen receptors. The poten-
tial of eplerenone to impact mortality and morbidity of post-infarction heart failure 
patients was the subject of the EPHESUS trial (Eplerenone Post-Acute Myocardial 
Infarction Heart Failure Efficacy and Survival Study). That multicenter, double-blind, 
randomized, international trial included 6.632 patients with AMI complicated by left 
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ventricular dysfunction (LVEF ≤40% by echocardiogram, 
radionuclide angiography, or left ventricular angiography) and 
clinical signs of heart failure (i.e., the presence of pulmonary 
rales, pulmonary venous congestion on chest radiograph, or the 
presence of a third heart sound). The clinical evidence of heart 
failure could be transient, occurring at any time from the onset 
of the index AMI, and did not necessarily need to be present 
at the time of randomization. Post-AMI patients with diabetes 
mellitus were only required to have an LVEF ≤40%. Eligible 
patients were randomized between 3 and 14 days after AMI 
to treatment with eplerenone in addition to standard medical 
therapy. Patients with a serum potassium concentration >5.0 
mmol/l or a serum creatinine concentration >2.5 mg/dl were 
excluded. The two primary end points were time to death from 
any cause and time to death from cardiovascular causes or 
first hospitalization for a cardiovascular event (heart failure, 
recurrent AMI, stroke or ventricular arrhythmia). The major 
secondary end points were death from cardiovascular causes 
and death from any cause or any hospitalization.
Finally, it was shown that eplerenone at a dose of 25 mg/
day, reduced total mortality by 31%, cardiovascular mortality 
by 32% and sudden cardiac death by 37% within 30 days of 
randomization after AMI. Risk reduction in mortality with 
eplerenone seemed to occur as early as 10 days after randomi-
zation and continued through the end of the study (the mean 
duration of follow-up was 16 months).4,5
The mechanisms by which eplerenone provides myocardial 
protection in patients with AMI complicated by left ventricular 
dysfunction and heart failure are not completely clear. Effects 
of aldosterone blockers on plasma volume and electrolyte 
excretion have been recognized for many years, and although 
these effects may have contributed to the benefit provided 
by eplerenone, other nonrenal mechanisms may be equally 
or more important. Eplerenone reduces coronary vascular 
inflammation and the risk of subsequent development of inter-
stitial fibrosis, reduces oxidative stress,6 improves endothelial 
dysfunction, attenuates platelet aggregation, decreases activa-
tion of matrix metalloproteinases and improves ventricular 
remodeling.7
In conclusion, eplerenone survival benefits are crystal clear 
in heart failure patients post-AMI. In the European Society 
of Cardiology Guidelines for the diagnosis and treatment of 
acute and chronic heart failure 20088, the following class I 
recommendation (level of evidence B) is put forth for aldos-
terone antagonists: “Unless contraindicated or not tolerated, 
the addition of a low-dose of an aldosterone antagonist should 
be considered in all patients with an LVEF ≤35% and severe 
symptomatic heart failure, i.e. currently New York heart As-
sociation (NYHA) functional class III-IV, in the absence of 
hyperkalemia and significant renal dysfunction. Aldosterone 
antagonists reduce hospital admission for worsening heart 
failure and increase survival when added to existing therapy, 
including an angiotensin converting enzyme inhibitor. In hos-
pitalized patients satisfying these criteria, treatment with an 
aldosterone antagonist should be initiated before discharge”.
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